Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Loula Papageorgiou, Patrick Van Dreden, PhD, Meletios A. Dimopoulos, MD, Annette Larsen, Mohamad Mohty, MD PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas

Blood (2019) 134 (Supplement_1): 2425.

https://doi.org/10.1182/blood-2019-124650

Published: 2019

Journal Articles

In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study

Grigorios T. Gerotziafas, Despina Fotiou, BMBS, MA, Patrick Van Dreden, PhD, Theodoros N Sergentanis, Ismail Elalamy, MD PhD, Loula Papageorgiou, Matthieu Grusse, Stella Salta, Theodora Psaltopoulou, Annette Larsen, Evangelos Terpos, MD PhD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2018-99-114871

Published: 2018

Journal Articles

Transmission of Procoagulant Properties to Daughter Generations of Endothelial Cells upon Exposure to Cancer Cell-Derived Microparticles. a New Implication of Cancer Derived Microparticles in the Pathogenesis of Cancer Associated Thrombosis

Rania Amrane, Aurélie Rousseau, PhD, Annette Larsen, Patrick Van Dreden, PhD, Grigorios T. Gerotziafas

Blood (2018) 132 (Supplement 1): 1231.

https://doi.org/10.1182/blood-2018-99-114685

Published: 2018

Journal Articles

Chemoresistant Colorectal Cancer (CRC) Cells Show Increased Invasive Potential Which Is Part Is Mediated By VEGF-Signaling and Can be Attenuated By VEGF-Directed Agents

Thouroude Sandrine, Patrick Van Dreden, PhD, Grigorios T. Gerotziafas, Annette Larsen

Blood (2018) 132 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2018-99-110202

Published: 2018

Journal Articles

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study

Grigorios T. Gerotziafas, MD PhD, Patrick Van Dreden, PhD, Stella Salta, Loula Papageorgiou, Paraskevi Boura, Annette Larsen, Jawed Fareed, PhD, Konstantinos Syrigos, Ismail Elalamy, MD PhD

Blood (2017) 130 (Supplement 1): 2381.

https://doi.org/10.1182/blood.V130.Suppl_1.2381.2381

Published: 2017

Journal Articles

Alteration of Endothelial Cell Hemostatic Equilibrium By Cancer Cell-Derived Microparticles, a New Insight in Pathogenesis of Cancer Associated Thrombosis

Aurélie Rousseau, PhD, Rania Amrane, Patrick Van Dreden, PhD, Loula Papageorgiou, Annette Larsen, Amir Khaterchi, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas, MD PhD

Blood (2017) 130 (Supplement 1): 3698.

https://doi.org/10.1182/blood.V130.Suppl_1.3698.3698

Published: 2017

Journal Articles

Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays

Grigorios T. Gerotziafas, MD PhD, Patrick Van Dreden, PhD, Walter Jeske, PhD, Jeanine M. Walenga, PhD, Debra Hoppensteadt, PhD, Annette Larsen, Ismail Elalamy, MD PhD, Yiming Yao, Jawed Fareed, PhD

Blood (2016) 128 (22): 5020.

https://doi.org/10.1182/blood.V128.22.5020.5020

Published: 2016

Journal Articles

Acquision of Resistance to Doxorubicin By Breast Cancer Cells MCF7 Enhances Their Procoagulant Properties and Alters the Efficacy of Antithrombotic Agents to Inhibit Thrombin Generation

Aurélie Rousseau, Patrick Van Dreden, PhD, Amir Khaterchi, Elisabeth Mbemba, Annette Larsen, Ismail Elalamy, MDPhD, Grigorios T. Gerotziafas, Dr

Blood (2015) 126 (23): 1113.

https://doi.org/10.1182/blood.V126.23.1113.1113

Published: 2015

Journal Articles

Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles

Grigorios T. Gerotziafas, Dr, Flora Zagouri, Despina Fotiou, Theodoros N. Sergentanis, Kimon Stamatelopoulos, Theodora Psaltopoulou, Efstathios Kastritis, MD, Evangelos Terpos, MD, Patrick Van Dreden, PhD, Aurélie Rousseau, Ilias Evmorfiadis, Ismail Elalamy, MDPhD, Annette Larsen, Meletios A. Dimopoulos

Blood (2015) 126 (23): 1074.

https://doi.org/10.1182/blood.V126.23.1074.1074

Published: 2015

Journal Articles

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Andrew M. Evens, Irene Helenowski, Erika Ramsdale, Chadi Nabhan, Reem Karmali, Britt Hanson, Benjamin Parsons, Scott Smith, Annette Larsen, June M. McKoy, Borko Jovanovic, Stephanie Gregory, Leo I. Gordon, Sonali M. Smith

Blood (2012) 119 (3): 692–695.

https://doi.org/10.1182/blood-2011-09-378414

Published: 2012

Includes: Supplemental data

Journal Articles

Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era

Andrew M. Evens, DO, MSc, Irene Helenowski, MS, Chadi Nabhan, MD, FACP, Erika Ramsdale, MD, June M McKoy, MD, JD, MPH, MBA, Annette Larsen, B.A., R.N., Sarah Miyata, RN, MSN, ACNP, Benjamin Parsons, DO, Reem Karmali, MD, Britt E. Hanson, DO, Leo I. Gordon, MD, FACP, Scott E. Smith, MD, PhD, FACP, Stephanie A. Gregory, MD, Sonali M. Smith, MD

Blood (2011) 118 (21): 2625.

https://doi.org/10.1182/blood.V118.21.2625.2625

Published: 2011

Journal Articles

Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,

Chadi Nabhan, MD, FACP, Sonali M. Smith, MD, Irene Helenowski, MS, Erika Ramsdale, MD, Reem Karmali, MD, Benjamin Parsons, DO, Josephine L. Feliciano, MD, Britt E. Hanson, DO, Scott E. Smith, MD, PhD, FACP, Annette Larsen, B.A., R.N., June M. McKoy, MD, MPH, JD, MBA, Stephanie A. Gregory, MD, Andrew M. Evens, DO, MSc

Blood (2011) 118 (21): 3668.

https://doi.org/10.1182/blood.V118.21.3668.3668

Published: 2011

Journal Articles

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Andrew M. Evens, DO, MSc, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD, FACP, Irene Helenowski, MS, Justin Kline, MD, Annette Larsen, B.A., R.N., Jane N. Winter, M.D., Sonali M. Smith, MD, Koen M. Van Besien, MD

Blood (2011) 118 (21): 1646.

https://doi.org/10.1182/blood.V118.21.1646.1646

Published: 2011

Journal Articles

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Rupali Roy, M.D., Andrew M Evens, DO, MSc, David P. Patton, B.S., Annette Larsen, B.S., R.N., Alfred Rademaker, Ph.D., Jeffrey Cilley, M.D., Stewart Spies, M.D., Daina Variakojis, M.D., Leo I Gordon, M.D., Jane N. Winter, M.D.

Blood (2010) 116 (21): 1749.

https://doi.org/10.1182/blood.V116.21.1749.1749

Published: 2010

Journal Articles

Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival

Andrew M Evens, DO, MSc, Chadi Nabhan, MD, FACP, Irene Helenowski, PhD, Annette Larsen, B.A., R.N., Erika E. Ramsdale, MD, Reem Karmali, MD, Josephine L. Feliciano, MD, Benjamin Parsons, MD, June M McKoy, MD, JD, MPH, MBA, Stephanie A. Gregory, MD, Sonali M Smith, MD

Blood (2010) 116 (21): 3124.

https://doi.org/10.1182/blood.V116.21.3124.3124

Published: 2010

NARROW

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study

Transmission of Procoagulant Properties to Daughter Generations of Endothelial Cells upon Exposure to Cancer Cell-Derived Microparticles. a New Implication of Cancer Derived Microparticles in the Pathogenesis of Cancer Associated Thrombosis

Chemoresistant Colorectal Cancer (CRC) Cells Show Increased Invasive Potential Which Is Part Is Mediated By VEGF-Signaling and Can be Attenuated By VEGF-Directed Agents

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer Associated Thrombosis. the Observational Roadmap-CAT Study

Alteration of Endothelial Cell Hemostatic Equilibrium By Cancer Cell-Derived Microparticles, a New Insight in Pathogenesis of Cancer Associated Thrombosis

Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays

Acquision of Resistance to Doxorubicin By Breast Cancer Cells MCF7 Enhances Their Procoagulant Properties and Alters the Efficacy of Antithrombotic Agents to Inhibit Thrombin Generation

Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era

Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only